Welldoc’s digital health platform, featuring the award-winning BlueStar for diabetes, scales a virtual channel of care across your population.
Learn about Digital HealthIn a prospective, randomized, controlled study, Quinn et al. (Diabetes Care, 2011) found that, individuals with type 2 diabetes whose A1C levels were poorly controlled (>9.0%) or abnormal (7.5-8.9%) at the time of enrollment, and who were randomized to use a mobile phone app to help them manage their diabetes in addition to usual care, improved A1C by an average 1.9%, compared with 0.7% improvement in persons randomized to usual care alone, a difference of 1.2% (P < 0.001) over 12 months.
The results from the study (Figure 1) indicate a hemoglobin A1C reduction of 1.9%, compared with 0.7% improvement in persons randomized to usual care alone, a difference of 1.2% (P < 0.001) over 12 months. The results stratified on baseline glycated hemoglobin show that the results in Figure 1 do not indicate regression to the mean. Figure 2 shows the results within strata of baseline A1C less than 9%, and Figure 3 shows the results within strata of baseline A1C greater than or equal to 9%.
In a prospective, randomized, controlled study, Quinn et al. (Diabetes Technology and Therapeutics, 2008) found that individuals whose A1C levels were greater than or equal to 7.5% within most recent three months and received Welldoc’s software experienced an average decrease in A1c of 2.03%. Patients in the control group obtained an average A1C reduction of 0.68% (P < 0.02, one-tailed). Of the intervention patients, 84% had medications titrated or changed by their HCP compared to controls (23%, P = 0.002).
Welldoc rigorously examines its products and their impact, as evidenced in over 45 peer-reviewed publications, posters, and presentations.
Clinical Studies J Med Internet Res
Clinical Studies J Med Internet Res
Clinical Studies ADA, New Orleans
Clinical Studies Diabetes Technology Therapeutics
Clinical Studies Journal of Applied Gerontology
Clinical Studies Journal of Diabetes Science and Technology
Clinical Studies Contemporary Clinical Trials
Clinical Studies Diabetes Care
Clinical Studies Diabetes Technol Ther
Clinical Studies Journal Name
Demonstration Project ADA, Boston
Demonstration Project Journal of Health Communications
Demonstration Project Journal Name
Frameworks Society of Behavioral Medicine
Frameworks Journal of Diabetes Science and Technology
Frameworks Encore Presentation at AADE 2018
Frameworks American Association of Diabetes Educators (AADE)
Frameworks American Association of Diabetes Educators
EMR Integration Journal of Diabetes Science and Technology
Post-Marketing Outcomes Diabetes Technology Society, Bethesda, MD
Post-Marketing Outcomes Diabetes Technology Society, Washington D.C.
Post-Marketing Outcomes ADA, Boston
Post-Marketing Outcomes ADA, Orlando
Whitepapers & Articles Today's Dietitian
Clinical Models AADE, New Orleans
Clinical Models Population Health Management
Clinical Models ADA, Orlando
Clinical Models AADE, Baltimore
Clinical Models AADE, San Antonio
Book Chapters mHealth Innovation: Best Practices from the Mobile Frontiers
Book Chapters Connected Health: Improving Care, Health, and Efficiency with Wearables
To test the relationship between A1C reduction and cost savings, we funded a retrospective analysis in partnership with IBM Watson Health. We provided IBM Watson Health starting and ending A1C data from 3,000+ of our BlueStar users. Documented A1C reductions associated with BlueStar are correlated with cost differences associated with the factors listed below.
Hospitalizations, ER visits, and HCP office visits
Cost of devices, supplies,
and medications
Cost of co-morbid complications
of diabetes
Claims data from patients in the IBM Watson Health's Market Scan Database, which captures claims data of more than 200 million individuals in the US.
The CDC predicts 1 out of every 3 people born in the US after the year 2000 will develop diabetes.
Once the patients were stratified by A1C band, the analysis was customized for the commercial sector and the Medicare sector.
Truven MarketScan Database: Annual Cost Per Patient is average amount paid for any healthcare claim within 365 days for: 1) patients with at least two lab results within the same A1c range ; and 2) patients with four lab results within the same A1C range. Percentage in Band Today is based on national attrition levels in Truven database.
Enter the number of members to the right for an estimation of the annual cost of diabetes in your population.
Click below to visit our contact us page, where you can request a copy of the white paper. Inside, you will find more information related to how we arrived at cost reductions by A1C band.
Fully HIPAA
Compliant
ISO 13485
Certified
FDA Cleared,
seven 510Ks, Rx and OTC IFU
SOC 2
Certified
"I can tell that diabetes experts are a part of this and have really honed in on what people need."
Watch Candy Barnes' BlueStar StoryWhat makes all of Welldoc’s software unique? There are a lot of tools that sound similar to ours out there, but no other solution is device agnostic, empowers the user’s existing care team, and scales at a population level.
We integrate seamlessly into your member’s life, allowing them to bring their own device instead of the one provided.
Illuminate data between in-office visits to facilitate better decision making and more productive visits.
AI-driven coaching reserves human touch-points for higher needs members
Our seasoned implementation leads help you choose a plan we are confident will succeed.
Our marketing team develops a plan to engage your unique population.
Our data scientists build models to forecast your ROI and engagement.
Our clinical experts ensure you have science to back up your decision.
